KLP Kapitalforvaltning AS Makes New $383,000 Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

KLP Kapitalforvaltning AS bought a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 14,900 shares of the company’s stock, valued at approximately $383,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. R Squared Ltd purchased a new position in IDEAYA Biosciences during the 4th quarter valued at about $35,000. Quantbot Technologies LP purchased a new position in shares of IDEAYA Biosciences during the third quarter valued at approximately $83,000. Daiwa Securities Group Inc. boosted its position in shares of IDEAYA Biosciences by 44.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company’s stock worth $72,000 after purchasing an additional 853 shares in the last quarter. KBC Group NV boosted its position in shares of IDEAYA Biosciences by 84.6% in the 4th quarter. KBC Group NV now owns 4,197 shares of the company’s stock worth $108,000 after purchasing an additional 1,923 shares in the last quarter. Finally, Paloma Partners Management Co purchased a new stake in shares of IDEAYA Biosciences in the 3rd quarter worth approximately $213,000. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Trading Down 5.5 %

NASDAQ:IDYA opened at $14.71 on Friday. The company has a market cap of $1.29 billion, a PE ratio of -4.46 and a beta of 0.51. The company has a 50 day simple moving average of $20.05 and a two-hundred day simple moving average of $25.19. IDEAYA Biosciences, Inc. has a 12 month low of $14.40 and a 12 month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.82). The company had revenue of $7.00 million during the quarter, compared to the consensus estimate of $7.00 million. Research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have commented on IDYA. Cantor Fitzgerald reissued an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Stephens reiterated an “overweight” rating and issued a $50.00 price target on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada restated an “outperform” rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Wedbush reiterated an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $53.58.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.